ABSTRACT
OBJECTIVES: The aim of this pilot study was to investigate the utility of haemodynamic parameters derived from dynamic contrast-enhanced computed tomography (DCE-CT) scans in the assessment of tumour response to treatment in malignant pleural mesothelioma (MPM) patients. METHODS: The patient cohort included nine patients undergoing chemotherapy and five patients on observation. Each patient underwent two DCE-CT scans separated by approximately 2 months. The DCE-CT parameters of tissue blood flow (BF) and tissue blood volume (BV) were obtained within the dynamically imaged tumour. Mean relative changes in tumour DCE-CT parameters between scans were compared between the on-treatment and on-observation cohorts. DCE-CT parameter changes were correlated with relative change in tumour bulk evaluated according to the modified RECIST protocol. RESULTS: Differing trends in relative change in BF and BV between scans were found between the two patient groups (p = 0.19 and p = 0.06 for BF and BV, respectively). No significant rank correlations were found when comparing relative changes in DCE-CT parameters with relative change in tumour bulk. CONCLUSIONS: Differing trends in the relative change of BF and BV between patients on treatment and on observation indicate the potential of DCE-CT for the assessment of pharmacodynamic endpoints with respect to treatment in MPM. A future study with a larger patient cohort and unified treatment regimens should be undertaken to confirm the results of this pilot study. KEY POINTS: ⢠CT-derived haemodynamic parameters show differing trends between malignant pleural mesothelioma patients on treatment and patients off treatment ⢠Changes in haemodynamic parameters do not correlate with changes in tumour bulk as measured according to the modified RECIST protocol ⢠Differing trends across the two patient groups indicate the potential sensitivity of DCE-CT to assess pharmacodynamic endpoints in the treatment of MPM.
Subject(s)
Antineoplastic Agents/therapeutic use , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/drug therapy , Mesothelioma/diagnostic imaging , Mesothelioma/drug therapy , Pleural Neoplasms/diagnostic imaging , Pleural Neoplasms/drug therapy , Aged , Aged, 80 and over , Antineoplastic Agents/pharmacology , Female , Hemodynamics/drug effects , Humans , Lung Neoplasms/blood supply , Lung Neoplasms/pathology , Male , Mesothelioma/blood supply , Mesothelioma/pathology , Mesothelioma, Malignant , Middle Aged , Neovascularization, Pathologic/diagnostic imaging , Pilot Projects , Pleural Neoplasms/blood supply , Pleural Neoplasms/pathology , Response Evaluation Criteria in Solid Tumors , Tomography, Spiral Computed/methods , Treatment OutcomeABSTRACT
Malignant pleural mesothelioma(MPM)is a highly aggressive tumor with a poor prognosis and an increasing incidence worldwide. The only standard first-line chemotherapy for patients with unresectable MPM is cisplatin(CDDP)plus peme- trexed(PEM)(CDDP/PEM), with a median overall survival of about 12months and a median progression-free survival(PFS) of less than 6 months. There are no treatments with proven benefit on survival for relapsed MPM patients. Therefore, novel therapeutic strategies are urgently required. Several molecular pathways involved in MPM have been identified; these include growth factor signaling pathways, cell cycle regulation, apoptosis, and angiogenesis. Fortunately, several agents targeting these processes have yielded promising results in preliminary trials. The addition of vascular endothelial growth factor(VEGF) inhibitor bevacizumab to the standard CDDP/PEM provides a 2.7-month survival benefit. Triple angiokinase inhibitor nintedanib, inhibiting the VEGFR, PDGFR, and FGFR, plus standard chemotherapy demonstrated a significant improvement in median PFS of 3.7 months in the overall study population, and a greater median PFS benefit of 4.0 months in epithelioid MPM. Mesothelin is an attractive target protein expressed on mesothelioma cells. Amatuximab, a chimeric anti-mesothelin antibody, in combination with CDDP/PEM, is currently being tested in randomized, double-blind, placebo-controlled phase II study. Anetumab ravtansine, mesothelin-directed antibody drug conjugate, was evaluated in a randomized trial to compare to vinorelbine in patients with MPM who have high mesothelin expression and have progressed on CDDP/PEM-based first-line chemotherapy. However, anetumab ravtansine was not superior to vinorelbine in primary endpoint of PFS(4.3 months vs 4.5 months). Immune checkpoint blockades have demonstrated promising preclinical and clinical results in several cancer types, and are currently being investigated in clinical trials for MPM patients. PD-L1 expression in tumor tissue of MPM was reported, ranging between 20% and 70%. PD-L1 expression was significantly associated with a worse survival and overexpression was more common in sarcomatoid histology. This review summarizes clinical results for the latest systemic treatments in MPM.
Subject(s)
Antineoplastic Agents/therapeutic use , Lung Neoplasms/drug therapy , Mesothelioma/drug therapy , Pleural Neoplasms/drug therapy , Humans , Lung Neoplasms/blood supply , Mesothelioma/blood supply , Mesothelioma, Malignant , Neovascularization, Pathologic , Pleural Neoplasms/blood supply , Pleural Neoplasms/pathologyABSTRACT
BACKGROUND: Standard chemotherapy does not lead to long-term survival in patients with malignant pleural mesothelioma. Malignant pleural mesothelioma is strongly dependent on vasculature with high vessel counts and high concentrations of serum vascular growth factors. Thalidomide has shown antiangiogenic activity, and we hypothesised that its use in the maintenance setting could improve outcomes. METHODS: In this open-label, multicentre, randomised phase 3 study, eligible patients had proven malignant pleural or peritoneal mesothelioma and had received a minimum of four cycles of first-line treatment containing at least pemetrexed, with or without cisplatin or carboplatin, and had not progressed on this treatment. Patients were randomly assigned (in a 1:1 ratio, stratified by previous first-line chemotherapy, histological subtype, and recruiting hospital) to receive thalidomide 200 mg per day (including a 2 week run in of 100 mg per day) plus active supportive care or active supportive care alone until disease progression. Patients were required to be registered and to start treatment with thalidomide within 10 weeks after the end of the first-line chemotherapy. Thalidomide was given for a maximum of 1 year or until unacceptable toxicity. The primary endpoint was time to progression. The primary analyses were by intention to treat. The study is registered, ISRCTN13632914. FINDINGS: Between May 11, 2004, and Dec 23, 2009, we randomly assigned 222 patients, 111 in each group (one patient on active supportive care later withdrew consent and was excluded from analyses). At the time of this final analysis, median follow-up was 33.1 months (IQR 22.3-66.8), and physician-reported disease progression had occurred in 104 patients in the thalidomide group and 107 in the active supportive care group; 92 patients in the thalidomide group and 93 in the active supportive care group had died. Median time to progression in the thalidomide group was 3·6 months (95% CI 3.2-4.1) compared with 3.5 months (2.3-4.8) in the active supportive care group (hazard ratio 0.95, 95% CI 0.73-1.20, p=0.72). 43 (39%) grade 3 or 4 adverse events were reported in the thalidomide group and 31 (28%) in the active supportive care group; neurosensory events were reported by two (2%) patients on thalidomide and none on active supportive care, cardiac events by two (2%) patients on thalidomide and three (3%) on active supportive care, and thromboembolic events by three (3%) patients on thalidomide and none on active supportive care. INTERPRETATION: No benefit was noted in time to progression with the addition of thalidomide maintenance to first-line chemotherapy. Different treatment strategies are needed to improve outcomes in patients with malignant mesothelioma. FUNDING: Dutch Cancer Society (KWF), Eli Lilly, NSW Dust Disease Compensation Board, University of Sydney, and Cancer Australia.
Subject(s)
Angiogenesis Inhibitors/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lung Neoplasms/drug therapy , Mesothelioma/drug therapy , Palliative Care , Pleural Neoplasms/drug therapy , Thalidomide/administration & dosage , Aged , Angiogenesis Inhibitors/adverse effects , Biomarkers, Tumor/blood , Carboplatin/administration & dosage , Chi-Square Distribution , Cisplatin/administration & dosage , Disease Progression , Drug Administration Schedule , Female , Glutamates/administration & dosage , Guanine/administration & dosage , Guanine/analogs & derivatives , Humans , Intention to Treat Analysis , Kaplan-Meier Estimate , Linear Models , Lung Neoplasms/blood , Lung Neoplasms/blood supply , Lung Neoplasms/pathology , Male , Mesothelioma/blood , Mesothelioma/blood supply , Mesothelioma/pathology , Mesothelioma, Malignant , Middle Aged , Multivariate Analysis , Pemetrexed , Pleural Neoplasms/blood , Pleural Neoplasms/blood supply , Pleural Neoplasms/pathology , Proportional Hazards Models , Thalidomide/adverse effects , Time Factors , Treatment OutcomeABSTRACT
BACKGROUND: The purpose of this study was to investigate the diagnostic and prognostic value of circulating endothelial cell (CEC), a potential surrogate of tumor angiogenesis, in malignant pleural mesothelioma (MPM). METHODS: We prospectively evaluated CEC count in 4.0 mL of peripheral blood sampled from patients with a suspicion of MPM. An automated system was used to capture CECs with an anti-CD146 antibody. RESULTS: Of 109 eligible patients, 30 were finally diagnosed with non-malignant diseases, and 79 were with MPM. CEC count was significantly higher in MPM patients than in NM patients (mean CEC count, 120.3 and 39.9, respectively; P = 0.001), and a receiver operating characteristic (ROC) curve analysis showed that CEC provided a significant diagnostic performance in discrimination between MPM and nonmalignant diseases with an area under curve (AUC-ROC) of 0.700 (95 % confidence interval [95 % CI], 0.595-0.806; P = 0.001). Among MPM patients, CEC count was positively correlated with intratumoral microvessel density (MVD), a measurement of tumor angiogenesis (Spearman correlation coefficiency [r] = 0.444; P = 0.001). Higher CEC count (>50) was significantly associated with a poor prognosis (median overall survival, 11.4 months [95 % CI, 7.6-15.2] for higher CEC count patients versus 20.1 months [95 % CI, 16.0-24.2] for lower CEC count patients; P = 0.028). A multivariate analysis showed that higher CEC count was a significant and independent factor to predict a poor prognosis (hazard ratio [HR], 2.24, [95 % CI, 1.24-4.43]; P = 0.009). CONCLUSIONS: CEC, as a surrogate of tumor angiogenesis, was a promising marker in diagnosis and prediction of prognosis in MPM.
Subject(s)
Biomarkers, Tumor/analysis , Endothelial Cells/pathology , Mesothelioma/diagnosis , Neoplastic Cells, Circulating/pathology , Neovascularization, Pathologic , Pleural Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Area Under Curve , Case-Control Studies , Female , Follow-Up Studies , Humans , Male , Mesothelioma/blood supply , Mesothelioma/mortality , Middle Aged , Neoplasm Staging , Pleural Neoplasms/blood supply , Pleural Neoplasms/mortality , Prognosis , Prospective Studies , Survival RateABSTRACT
NK4 exhibits two distinct biological actions: antagonistic inhibition of hepatocyte growth factor (HGF) through binding to the Met/HGF receptor, and antiangiogenic action through binding to perlecan. Here, the anti-tumor effect of NK4 on malignant pleural mesothelioma was investigated. Of the 7 human malignant mesothelioma cell lines (ACC-Meso-1, ACC-Meso-4, EHMES-1, EHMES-10, H28, H2052 and JMN-1B), only EHMES-10 cells formed subcutaneous tumors when implanted into mice. For EHMES-10 cells, HGF facilitated invasion of the cells in collagen gel, whereas NK4 and neutralizing anti-HGF antibody suppressed the HGF-induced invasion. In addition, NK4 but not anti-HGF antibody suppressed proliferation of EHMES-10 cells in collagen, suggesting that the suppression by NK4 was independent of the HGF-Met pathway. In the subcutaneous tumor model, recombinant adenovirus-mediated intratumoral expression of NK4 inhibited tumor growth, while the invasive characteristic of tumor cells was not observed. Analysis of Met receptor tyrosine phosphorylation, proliferation, apoptosis and blood vessels in the tumor tissues indicated that the inhibitory effect of NK4 expression might be primarily caused by the inhibition of tumor angiogenesis. In all the 7 mesothelioma lines, HGF stimulated Met tyrosine phosphorylation, and this was associated with enhanced cell migration. HGF-dependent Met activation and migration were inhibited by NK4. Since malignant pleural mesothelioma represents an aggressive neoplasm characterized by extensive invasive growth, suppression of invasive growth has therapeutic value. Thus, the simultaneous inhibition of the HGF-Met pathway and angiogenesis by NK4 for treatment of malignant pleural mesothelioma is significant, particularly to attenuate migration and invasive growth.
Subject(s)
Cell Movement , Hepatocyte Growth Factor/physiology , Mesothelioma/pathology , Neovascularization, Pathologic/prevention & control , Pleural Effusion, Malignant/prevention & control , Pleural Neoplasms/pathology , Proto-Oncogene Proteins c-met/antagonists & inhibitors , Adenoviridae/genetics , Animals , Blotting, Western , Cell Adhesion , Cell Proliferation , Gene Expression , Genetic Vectors , Humans , Immunoenzyme Techniques , Immunoprecipitation , Male , Mesothelioma/blood supply , Mice , Mice, Inbred BALB C , Mice, Nude , Phosphorylation , Pleural Effusion, Malignant/metabolism , Pleural Effusion, Malignant/pathology , Pleural Neoplasms/blood supply , Proto-Oncogene Proteins c-met/genetics , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , Transfection , Tumor Cells, CulturedABSTRACT
BACKGROUND: Administration of interleukin-2 (IL-2) has shown some effects on malignant pleural mesothelioma (MPM) tumour regression. The purpose of this study was to investigate the ability of IL-2 to modify immunological effector cells and angiogenesis in MPM patients and their prognostic value. METHODS: Tumour-infiltrating lymphocytes (CD4, CD8, Foxp3), mast cells (MCs) (tryptase and chymase), microvessel count (MVC) and VEGF were determined by immunohistochemistry in two series of MPM patients: 60 patients treated with intra-pleural preoperative IL-2 and 33 patients untreated. RESULTS: Tryptase MCs, and CD8 and Foxp3 lymphocytes were significantly increased in the IL-2-treated group, whereas MVC was significantly lower in the same group. Moreover, in the IL-2-treated group, greater tryptase+MCs and greater Foxp3 lymphocytes were associated with improved and poorer clinical outcomes, respectively. Notably, when these two immunological parameters were combined, they predicted outcomes more effectively. CONCLUSIONS: This study showed that IL-2 treatment leads to a significant increase of immunological parameters, concomitantly with a reduction in vasculature, providing new insight into the cancer mechanisms mediated by IL-2. Moreover, these results suggest that tryptase-positive MCs and Foxp3+ lymphocytes predict clinical outcomes in IL-2-treated patients, highlighting the critical role of the inflammatory response in mesothelioma cancer progression.
Subject(s)
Interleukin-2/therapeutic use , Mesothelioma/drug therapy , Pleural Neoplasms/drug therapy , Adult , Aged , Disease Progression , Female , Forkhead Transcription Factors/immunology , Humans , Immunohistochemistry , Interleukin-2/immunology , Lymphocytes/immunology , Lymphocytes, Tumor-Infiltrating/pathology , Male , Mast Cells/immunology , Mesothelioma/blood supply , Mesothelioma/immunology , Mesothelioma/pathology , Middle Aged , Multivariate Analysis , Neovascularization, Pathologic/drug therapy , Neovascularization, Pathologic/immunology , Pleural Neoplasms/blood supply , Pleural Neoplasms/immunology , Pleural Neoplasms/pathology , Prognosis , Survival Rate , Treatment Outcome , Tryptases/immunologyABSTRACT
Placenta growth factor (PlGF) is a key regulator of pathological angiogenesis and its overexpression has been linked to neoplastic progression. To assess whether PlGF could have a role in malignant mesothelioma (MM), we analyzed the expression of PlGF, VEGF, and their cognate receptors (VEGF-R1 and VEGF-R2) and co-receptors (neuropilin-1 and neuropilin-2) in MM cell lines as well as in resected MM tissues, hyperplastic/reactive mesothelium and normal mesothelium. MM cell cultures expressed both ligands and the associated receptors to a variable extent and released different amounts of PlGF. As assessed by immunohistochemistry, PlGF expression was switched on in hyperplastic/reactive compared to normal mesothelium. Moreover, 74 and 94 percent of MM tissues overexpressed PlGF and VEGF-R1, respectively (p<0.05 MM vs normal mesothelium). Administration of recombinant PlGF-2 did not elicit a significant stimulation of MM cell growth, while it was associated with a transient phosphorylation of Akt, suggesting that PlGF-2 could activate downstream effectors of proliferative and cytoprotective signals via VEGF-R1 in MM cells. Indeed, the administration of an anti-PlGF antibody was found to cause a significant reduction of MM cell survival. In conclusion, our data demonstrate that, by acting as a survival factor, PlGF can play a role which goes beyond the stimulation of angiogenesis in MM. This evidence could help the rational design of new therapeutic interventions for this aggressive tumor.
Subject(s)
Epithelium/metabolism , Mesothelioma/metabolism , Pleural Neoplasms/metabolism , Pregnancy Proteins/metabolism , Cell Death , Cell Line , Cell Proliferation , Cell Survival , Epithelium/pathology , Gene Expression Regulation, Neoplastic , Humans , Hyperplasia , Mesothelioma/blood supply , Mesothelioma/genetics , Mesothelioma/pathology , Neovascularization, Pathologic/metabolism , Neuropilin-1/metabolism , Neuropilin-2/metabolism , Phosphorylation , Placenta Growth Factor , Pleural Neoplasms/blood supply , Pleural Neoplasms/genetics , Pleural Neoplasms/pathology , Pregnancy Proteins/genetics , Proto-Oncogene Proteins c-akt/metabolism , RNA, Messenger/metabolism , Recombinant Proteins/metabolism , Time Factors , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor Receptor-1/metabolism , Vascular Endothelial Growth Factor Receptor-2/metabolismABSTRACT
BACKGROUND: Narrow band imaging (NBI), which enhances blood vessels, is a new endoscopic technology for diagnosing malignancies, but it has not been investigated for pleuroscopy. OBJECTIVES: To evaluate the efficacy of NBI applied to pleuroscopy for detecting malignant lesions by assessing vascular patterns of the pleura. METHODS: From May 2006 to September 2008, 45 patients with undiagnosed pleural ef-fusion underwent pleuroscopy using a pleura-videoscope with white light (WL) and NBI under local anesthesia. For this prospective study, 73 biopsy specimens were obtained from sites where images under both WL and NBI were recorded and classified regarding vascular patterns. RESULTS: Of the 73 lesions, WL showed blood vessels in 32 lesions, and NBI in 52 lesions (WL vs. NBI; p = 0.0014). The accuracy, sensitivity and specificity in the detection of irregular vascular patterns, e.g. blood vessels with irregular caliber or punctate vessels indicating malignant lesions, were 60.3, 76.5 and 55.4% in WL, and 80.8, 85.3 and 76.9% in NBI, respectively, resulting in a significant increase in NBI (p = 0.0106 for accuracy and p = 0.0494 for specificity). For flat lesions, NBI revealed a higher accuracy rate (90.6%) in the detection of irregular vascular patterns indicating malignant lesions. CONCLUSION: Our study demonstrated that NBI applied to pleuroscopy displayed blood vessels significantly better than WL. NBI was useful to detect irregular vascular patterns suggesting malignant lesions, especially for flat lesions. Therefore, NBI was considered useful in the selection of optimal biopsy sites by assessing vascular patterns.
Subject(s)
Narrow Band Imaging , Pleural Neoplasms/diagnosis , Thoracoscopy , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Pleura/blood supply , Pleural Neoplasms/blood supply , Prospective StudiesABSTRACT
RATIONALE: Aminobiphosphonates, such as zoledronic acid (ZA), exert potent indirect antitumor effects and are currently being tested against human solid tumors. The antitumor actions of aminobiphosphonates, including angiostasis, are relevant to the pathogenesis of malignant pleural effusion (MPE), but no study has addressed the efficacy of these compounds against malignant pleural disease. OBJECTIVES: Here we hypothesized that treatment of immunocompetent mice with ZA would halt tumor progression in a mouse model of adenocarcinoma-induced MPE. METHODS: To induce MPE in mice, Lewis lung carcinoma cells were delivered directly into the pleural space. Subsequently, animals were treated with ZA in both a prevention and a regression protocol. MEASUREMENTS AND MAIN RESULTS: ZA treatment resulted in significant reductions in pleural fluid accumulation and tumor dissemination, while it significantly prolonged survival. These effects of ZA were linked to enhanced apoptosis of pleural tumor cells, decreased formation of new vessels in pleural tumors, and reduced pleural vascular permeability. In addition, ZA was able to inhibit the recruitment of mononuclear cells to pleural tumors, with concomitant reductions in matrix metalloproteinase-9 release into the pleural space. Finally, ZA limited the expression of proinflammatory and angiogenic mediators, as well as the activity of small GTP proteins Ras and RhoA, in tumor cells in vivo and in vitro. CONCLUSIONS: ZA is effective against experimental MPE, suggesting that this intervention should be considered for testing in clinical trials.
Subject(s)
Diphosphonates/therapeutic use , Imidazoles/therapeutic use , Pleural Effusion, Malignant/drug therapy , Animals , Apoptosis/drug effects , Capillary Permeability , Carcinoma, Lewis Lung/complications , Cell Line, Tumor , Cell Proliferation/drug effects , Diphosphonates/pharmacology , Imidazoles/pharmacology , Leukocytes, Mononuclear/pathology , Lung Neoplasms/complications , Macrophages/pathology , Male , Mice , Mice, Inbred C57BL , Neoplasm Transplantation , Neovascularization, Pathologic , Pleural Effusion, Malignant/etiology , Pleural Neoplasms/blood supply , Pleural Neoplasms/complications , Pleural Neoplasms/pathology , Zoledronic AcidABSTRACT
Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a poor prognosis, therefore development of novel effective therapies is urgent. In the present study, we investigated the therapeutic efficacy of vandetanib (ZD6474), an inhibitor of VEGFR-2, EGFR and RET tyrosine kinases, in an orthotopic model of MPM. We found that a human MPM cell line, EHMES-10, expressed RET/PTC3 oncogenic rearrangement and a large amount of VEGF. Vandetanib induced the apoptosis and inhibited the proliferation of EHMES-10 cells in vitro (IC(50)=0.3 microM). Once-daily oral treatment with vandetanib inhibited tumor angiogenesis, and reduced significantly the growth of thoracic tumors and the production of pleural effusions, resulting in the prolonged survival of mice in EHMES-10 orthograft model. In contrast, the selective EGFR tyrosine kinase inhibitor, gefitinib, had no effect against EHMES-10 cells both in vitro and in vivo. Our results suggest that using vandetanib to target RET-dependent tumor cell proliferation and survival and VEGFR-2-dependent tumor angiogenesis may be promising against MPM expressing RET oncogenic rearrangement and VEGF.
Subject(s)
Angiogenesis Inhibitors/pharmacology , Apoptosis , Gene Rearrangement , Mesothelioma/drug therapy , Piperidines/pharmacology , Pleural Neoplasms/drug therapy , Proto-Oncogene Proteins c-ret/biosynthesis , Quinazolines/pharmacology , Angiogenesis Inhibitors/therapeutic use , Animals , Base Sequence , Cell Line, Tumor , Cell Proliferation/drug effects , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/metabolism , Gefitinib , Humans , Male , Mesothelioma/blood supply , Mesothelioma/metabolism , Mice , Mice, SCID , Molecular Sequence Data , Neoplasm Transplantation , Neovascularization, Pathologic , Piperidines/therapeutic use , Pleural Neoplasms/blood supply , Pleural Neoplasms/metabolism , Proto-Oncogene Proteins c-ret/genetics , Quinazolines/therapeutic use , Transplantation, Heterologous , Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors , Vascular Endothelial Growth Factor Receptor-2/metabolismABSTRACT
RATIONALE AND OBJECTIVES: Malignant mesothelioma (MM) of the pleura is an aggressive and often fatal neoplasm. Because MM frequently demonstrates marked angiogenesis, it may be responsive to antiangiogenic therapy, but effective methods for selecting and monitoring of patients are further needed. We employed dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and quantitative immunohistochemistry (IHC) to characterize the microvascularity of MM using both a physiologic and ultrastructural method. MATERIALS AND METHODS: Nineteen patients diagnosed with MM were enrolled and DCE-MRI was performed before antiangiogenic treatment. For each patient, tumor regions were characterized by their DCE-MRI-derived pharmacokinetic parameters (Amp, k(ep), k(el)), which were also compared to those of normal tissue (aorta, liver, spleen, and muscle). In addition, quantitative IHC of representative samples was performed with CD-34 staining to compare the calculated microvessel density (MVD) results with DCE-MRI results. RESULTS: MM demonstrated markedly abnormal pharmacokinetic properties compared with normal tissues. Among the parameters tested, Amp was significantly different in MM (P < or = .001) compared to normal organs. Despite the observation that the MVD of mesotheliomas in this series was high compared to other tumors, DCE-MRI pharmacokinetic parameters had a moderately positive correlation with MVD (r = 0.5). CONCLUSIONS: DCE-MRI and IHC can be used in patients with MM to visualize tumor microvascularity and to characterize tumor heterogeneity. DCE-MRI and IHC results positively correlated, though moderately, but these two methods present as essential tumor biomarkers. This multimodal characterization may be useful in selecting possible tumor subtypes that would benefit from antiangiogenic therapy.
Subject(s)
Contrast Media/pharmacokinetics , Gadolinium DTPA/pharmacokinetics , Magnetic Resonance Imaging , Mesothelioma/blood supply , Mesothelioma/metabolism , Microcirculation , Pleural Neoplasms/blood supply , Pleural Neoplasms/metabolism , Aged , Female , Humans , Immunohistochemistry , Male , Mesothelioma/pathology , Middle Aged , Pleural Neoplasms/pathologyABSTRACT
Blue rubber bleb nevus syndrome (BRBNS) is a rare condition that consists of multiple venous malformations involving several organ systems, particularly the skin and the gastrointestinal tract, but any part of the body may be affected. Less than 250 cases have been reported in the literature. The authors describe the thoracic, abdominal, and pelvic imaging characteristics at computed tomography (CT) in a 50-year-old man with BRBNS.
Subject(s)
Nevus, Blue/diagnostic imaging , Skin Neoplasms/diagnostic imaging , Tomography, X-Ray Computed , Contrast Media , Diagnosis, Differential , Humans , Intestinal Neoplasms/blood supply , Intestinal Neoplasms/diagnostic imaging , Intestinal Neoplasms/pathology , Male , Middle Aged , Nevus, Blue/blood supply , Nevus, Blue/pathology , Pleural Neoplasms/blood supply , Pleural Neoplasms/diagnostic imaging , Pleural Neoplasms/pathology , Skin Neoplasms/blood supply , Skin Neoplasms/pathology , SyndromeABSTRACT
Malignant mesothelioma (MM) is a fatal tumour of increasing incidence which is related to asbestos exposure. This work evaluated expression in MM of Epidermal Growth Factor Receptor (EGFR) by immunohistochemistry in 168 tumour sections and its correlations with clinicopathological and biological factors. The microvessel density (MVD) was derived from CD34 immunostained sections. Hematoxylin and eosin stained sections were examined for intratumoural necrosis. COX-2 protein expression was evaluated with semi-quantitative Western blotting of homogenised tumour supernatants (n=45). EGFR expression was correlated with survival by Kaplan-Meier and log rank analysis. Univariate and multivariate Cox proportional hazards models were used to compare the effects of EGFR with clinicopathological and biological prognostic factors and prognostic scoring systems. EGFR expression was identified in 74 cases (44%) and correlated with epithelioid cell type (p<0.0001), good performance status (p<0.0001), the absence of chest pain (p<0.0001) and the presence of TN (p=0.004), but not MVD or COX-2. EGFR expression was a good prognostic factor in univariate analysis (p=0.01). Independent indicators of poor prognosis in multivariate analysis were non-epithelioid cell type (p=0.0001), weight loss, performance status and WBC>8.3x10(9)L(-1). EGFR status was not an independent prognostic factor. EGFR expression in MM correlates with epithelioid histology and TN. EGFR may be a target for selective therapies in MM.
Subject(s)
Biomarkers, Tumor/analysis , ErbB Receptors/analysis , Mesothelioma/mortality , Pleural Neoplasms/mortality , Cyclooxygenase 2/analysis , Female , Humans , Immunohistochemistry , Male , Membrane Proteins/analysis , Mesothelioma/blood supply , Mesothelioma/pathology , Multivariate Analysis , Neovascularization, Pathologic/pathology , Pleural Neoplasms/blood supply , Pleural Neoplasms/pathology , Prognosis , Proportional Hazards Models , Survival Analysis , Survival RateABSTRACT
BACKGROUND: This study aimed to evaluate the impact of selective abrogation of either the MEK/ERK1/2 (UO126 or PD98059) or the PI3K/AKT (LY294002) signaling cascade on cell proliferation, motility and invasion and production of VEGF (collectively termed pro-metastasis phenotypes) in cultured malignant pleural mesothelioma (MPM) cells. MATERIALS AND METHODS: Treatment-induced cytotoxicity was evaluated by MTT or Annexin V assays. Cell motility was assessed by wound healing and Matrigel invasion assays. VEGF in conditioned media of cancer cells was measured by ELISA. RESULTS: LY294002 and UO126 significantly inhibited cell proliferation and clonogenicity of MPM cells in vitro. A substantial reduction of cell motility, Matrigel invasion as well as inhibition of basal or EGF-induced VEGF production were observed in drug-treated cells. CONCLUSION: The selective MEK or PI3K kinase inhibitors are equally effective in down-regulating the expression of pro-metastasis phenotypes, suggesting that MEK or PI3K are appropriate targets for the development of molecular therapeutics for malignant pleural mesothelioma.
Subject(s)
Butadienes/pharmacology , Chromones/pharmacology , MAP Kinase Kinase Kinases/antagonists & inhibitors , Mesothelioma/drug therapy , Mesothelioma/secondary , Morpholines/pharmacology , Nitriles/pharmacology , Phosphoinositide-3 Kinase Inhibitors , Pleural Neoplasms/drug therapy , Pleural Neoplasms/pathology , Cell Line, Tumor , Cell Movement/drug effects , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Humans , Interleukin-8/biosynthesis , Mesothelioma/blood supply , Mesothelioma/enzymology , Neoplasm Metastasis , Neovascularization, Pathologic/drug therapy , Neovascularization, Pathologic/enzymology , Neovascularization, Pathologic/pathology , Pleural Neoplasms/blood supply , Pleural Neoplasms/enzymology , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Quinazolines/pharmacology , Vascular Endothelial Growth Factor A/biosynthesisABSTRACT
Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor that secretes various angiogenic factors. The main inhibitor of plasminogen activators, PAI-1 (SERPINE1), has been implicated in tumor progression and angiogenesis, and high PAI-1 expression has been associated with poor prognosis in MPM patients. In this study, we examined the antiangiogenic effects of PAI-1 inhibition in MPM. We administered the PAI-1 inhibitor, SK-216, to orthotopic mouse models in which MPM cells expressing high levels of VEGF (VEGFA) or bFGF (FGF2) were intrapleurally transplanted. SK-216 administration reduced tumor weights and the degree of angiogenesis in intrapleural tumors, irrespective of their angiogenic expression profiles. In addition, a combination of SK-216 and the chemotherapeutic agent cisplatin significantly reduced tumor weights compared with monotherapy, prolonging the survival of animals compared with cisplatin treatment alone. Furthermore, SK-216 inhibited migration and tube formation of cultured human umbilical vein endothelial cells induced by various angiogenic factors known to be secreted by MPM. These findings suggest that PAI-1 inactivation by SK-216 may represent a general strategy for inhibiting angiogenesis, including for the treatment of MPM. Cancer Res; 76(11); 3285-94. ©2016 AACR.
Subject(s)
Angiogenesis Inhibitors/pharmacology , Benzoxazoles/pharmacology , Dicarboxylic Acids/pharmacology , Lung Neoplasms/prevention & control , Mesothelioma/prevention & control , Neovascularization, Pathologic/drug therapy , Plasminogen Activator Inhibitor 1/chemistry , Pleural Neoplasms/prevention & control , Animals , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Biomarkers, Tumor/metabolism , Blotting, Western , Cell Movement/drug effects , Cell Proliferation/drug effects , Cisplatin/pharmacology , Drug Therapy, Combination , Humans , Lung Neoplasms/blood supply , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Mesothelioma/blood supply , Mesothelioma/metabolism , Mesothelioma/pathology , Mesothelioma, Malignant , Mice , Plasminogen Activator Inhibitor 1/metabolism , Pleural Neoplasms/blood supply , Pleural Neoplasms/metabolism , Pleural Neoplasms/pathology , Tumor Cells, Cultured , Xenograft Model Antitumor AssaysABSTRACT
The effects of 1-oleoyl lysophosphatidic acid on the induction of metastasis from intestinal adenocarcinomas induced in rats by azoxymethane and on RhoA activity in the tumors were investigated in male Wistar rats. Rats were given a weekly s.c. injection of azoxymethane (7.4 mg/kg body weight) for 10 weeks and, from week 16, s.c. injection of lysophosphatidic acid (5 or 15 microg/kg body weight) every other day until the end of the experiment in week 45. Lysophosphatidic acid at both dosages significantly increased the incidence of peritoneal metastasis. Its administration at higher dosage also significantly enhanced the development of pleural metastasis. Although lysophosphatidic acid at both dosages had little or no effect on the location, histologic type, depth of involvement or infiltrating growth patterns of the tumors, its administration at both dosages significantly increased the incidence of vessel invasion of adenocarcinomas. Lysophosphatidic acid also increased the activity of RhoA in the tumors, but not the cellular proliferation and vascularity of the colon tumors. Our findings indicate that lysophosphatidic acid significantly increased the incidence of peritoneal and/or pleural metastases from intestinal adenocarcinomas induced in rats by azoxymethane through RhoA activation.
Subject(s)
Adenocarcinoma/secondary , Intestinal Neoplasms/chemically induced , Lysophospholipids/pharmacology , Peritoneal Neoplasms/secondary , Pleural Neoplasms/secondary , rhoA GTP-Binding Protein/metabolism , Adenocarcinoma/blood supply , Adenocarcinoma/chemically induced , Adenocarcinoma/metabolism , Animals , Azoxymethane , Body Weight , Carcinogens , Colonic Neoplasms , Intestinal Neoplasms/pathology , Male , Peritoneal Neoplasms/blood supply , Peritoneal Neoplasms/metabolism , Pleural Neoplasms/blood supply , Pleural Neoplasms/metabolism , Proliferating Cell Nuclear Antigen/metabolism , Rats , Rats, WistarABSTRACT
The expression of angiogenic factors may represent useful markers for diagnosis and prediction of disease outcome. Basic fibroblast growth factor (b-FGF) is a potent angiogenic factor which promotes in vitro growth of endothelial cells and in vivo vessel formation. We investigated the expression of b-FGF in patients affected with malignant and non-malignant pleural diseases and presenting clinically with non-specific signs and symptoms. We also studied the relationships between the expression of b-FGF in patients with malignant pleural mesothelioma (MM) and tumour aggressiveness, assessed as tumour vessel density (TVD), or patient survival. Basic-FGF was measured by immunoassay in the serum and pleural effusions (PE) of 37 patients. Of these, MM was diagnosed in 15/37 patients while the remaining patients had either peripheral lung adenocarcinoma (PLA) or benign inflammatory pleural disease (BPD). The mean b-FGF level measured 8.5+/-6.1 pg/ml in the PE of the malignant group (MM + PLA) and 23.9+/-19.8 in the PE of the non-malignant group (BPD) (p=0.001). The mean b-FGF level was significantly lower in the PE of MM patients (6.9+/-5.2 pg/ml) compared to BPD patients (p=0.004). Linear regression analysis showed a significant inverse correlation (r=-0.59; p=0.041) between b-FGF levels found in MM PE and patient survival. A noteworthy relationship between high serum b-FGF levels and reduced survival was also observed (r=-0.57; p=0.052). Interestingly, both serum (r=0.48; p=0.114) and PE (r=0.26; p=0.413) b-FGF levels in MM patients correlated poorly with TVD. Our data indicate that b-FGF is significantly more expressed in non-malignant compared to malignant PE, this difference being particularly evident between MM and BPD. Our results also suggest that high b-FGF levels correlate with poor MM patient survival through mechanisms which may be independent of b-FGF angiogenic potential.
Subject(s)
Biomarkers, Tumor/metabolism , Fibroblast Growth Factor 2/metabolism , Mesothelioma/mortality , Neoplasms, Mesothelial/mortality , Neovascularization, Pathologic/metabolism , Pleural Effusion, Malignant/metabolism , Pleural Neoplasms/mortality , Adult , Aged , Aged, 80 and over , Cell Division/drug effects , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Factor VIII/metabolism , Female , Humans , Male , Mesothelioma/blood supply , Mesothelioma/metabolism , Microscopy, Electron , Middle Aged , Neoplasms, Mesothelial/blood supply , Neoplasms, Mesothelial/metabolism , Pleural Neoplasms/blood supply , Pleural Neoplasms/metabolism , Survival Rate , Tumor Cells, CulturedABSTRACT
OBJECTIVES: Malignant mesothelioma (MM) is a fatal tumor of increasing incidence related to asbestos exposure. Microscopic tumor necrosis (TN) is a poor prognostic factor in solid tumors, but it has not been characterized in MM. We wished to evaluate the incidence of TN in MM and its correlations with clinicopathologic factors, angiogenesis, and survival. METHODS: TN was graded in 171 routine formalin-fixed, paraffin-embedded hematoxylin-eosin-stained tumor sections by two independent observers. Angiogenesis was assessed by the microvessel count (MVC) of CD34 immunostained sections. TN was correlated with survival by Kaplan-Meier and log-rank analysis, and stepwise, multivariate Cox models were used to compare TN with angiogenesis and established prognostic factors and prognostic scoring systems. RESULTS: TN was identified in 39 cases (22.8%) and correlated with low hemoglobin (p = 0.01), thrombocytosis (p = 0.04), and high MVC (p = 0.02). TN was a poor prognostic factor in univariate analysis (p = 0.008). Patients with TN had a median survival of 5.3 months vs 8.3 months in negative cases. Independent indicators of poor prognosis in multivariate analysis were nonepithelioid cell type (p = 0.0001), performance status > 0 (p = 0.007), and increasing MVC (p = 0.004) but not TN. TN contributed independently to the European Organisation for Research and Treatment of Cancer (EORTC) [p = 0.03] and to the Cancer and Leukemia Group B (CALGB) [p = 0.03] prognostic groups in respective multivariate Cox analyses. CONCLUSIONS: TN correlates with angiogenesis and is a poor prognostic factor in MM. TN contributes to the EORTC and CALGB prognostic scoring systems.
Subject(s)
Mesothelioma/pathology , Neovascularization, Pathologic/pathology , Pleural Neoplasms/pathology , Female , Humans , Male , Mesothelioma/blood supply , Mesothelioma/mortality , Middle Aged , Multivariate Analysis , Necrosis , Pleural Neoplasms/blood supply , Pleural Neoplasms/mortality , Prognosis , Proportional Hazards Models , Survival RateABSTRACT
Hepatocyte growth factor/scatter factor (HGF/SF) stimulates cell proliferation, motility and invasiveness via its receptor c-Met during embryogenesis and repair processes. It induces angiogenesis, promoting endothelial cell migration and capillary-tube formation in vivo. Co-expression of HGF/SF and c-Met receptor results in enhanced tumour growth, invasiveness and a mesenchymal-epithelial transition in some experimental tumours. Since mesothelioma cells have been reported to express c-Met receptor and to migrate in response to HGF/SF, we investigated human malignant pleural mesotheliomas for the demonstration of possible co-expression of the growth factor and its receptor. The microvessel density of the tumours was also analysed in order to assess the influence of HGF/SF expression on tumour angiogenesis. Thirty-nine paraffin-embedded specimens of malignant pleural mesotheliomas were immunostained by anti-HGF/SF and anti-c-Met antibodies and semiquantitatively evaluated. c-Met mRNA expression was visualised in ten tumour samples by a fluorescent in situ hybridisation method. Microvessel density was calculated by counting microvessels with a high-power field (200x) on von-Willebrand-factor-stained slides. We found an increased production of HGF/SF in 33/39 tumours and a corresponding overexpression of c-Met receptor in 29/39 specimens. The FISH method detected increased transcription of c-Met mRNA in malignant cells and in neighbouring vascular endothelial cells. HGF/SF-positive mesotheliomas had significantly higher microvessel densities compared to their HGF/SF-negative counterparts. The observed co-expression of HGF/SF and c-Met in malignant pleural mesotheliomas suggests a possible self-stimulation (autocrine loop) of tumour cells. On the basis of the significantly higher microvessel density values of malignant mesotheliomas overexpressing HGF/SF, we postulate, that HGF/SF may be an additional relevant factor in tumour angiogenesis in malignant pleural mesotheliomas.
Subject(s)
Hepatocyte Growth Factor/physiology , Mesothelioma/blood supply , Mesothelioma/metabolism , Pleural Neoplasms/blood supply , Pleural Neoplasms/metabolism , Proto-Oncogene Proteins c-met/physiology , Hepatocyte Growth Factor/biosynthesis , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Neovascularization, Pathologic/metabolism , Proto-Oncogene Proteins c-met/biosynthesisABSTRACT
Angiogenesis is an important part of normal and pathological processes, including tumour growth, metastasis, inflammation and wound healing. VEGF is the best known angiogenic factor, implicated in tumour-associated microvascular hyperpermeability and carcinogenesis. We investigated 103 malignant pleural mesotheliomas, analysing the expression of vascular endothelial growth factor using immunohistochemistry and in situ hybridization. The grade of microvessel density was assessed with the aid of anti-factor-VIII antibodies. An increased expression of VEGF was found in biphasic and epithelioid mesotheliomas, correlating in a statistically significant manner (P<0.042). In situ hybridization confirmed the specificity of VEGF mRNA expression. There was a robust correlation between VEGF expression and increased microvessel density (P<0.001), and positive mesotheliomas had significantly higher microvessel densities than negative specimens. There was also a significant correlation between microvessel density and histological pattern. As growth pattern tended towards biphasic and sarcomatoid mesotheliomas the density of micovessels decreased (P<0.05).